Lantheus (NASDAQ:LNTH) Price Target Raised to $141.00 at Truist Financial

Lantheus (NASDAQ:LNTHGet Free Report) had its price objective hoisted by equities research analysts at Truist Financial from $96.00 to $141.00 in a research note issued to investors on Thursday, Benzinga reports. The brokerage presently has a “buy” rating on the medical equipment provider’s stock. Truist Financial’s price objective would indicate a potential upside of 32.79% from the company’s previous close.

Other equities research analysts have also recently issued research reports about the stock. SVB Leerink raised their target price on shares of Lantheus from $106.00 to $127.00 and gave the stock an “outperform” rating in a research note on Thursday. B. Riley raised their target price on shares of Lantheus from $95.00 to $99.00 and gave the stock a “buy” rating in a research note on Thursday, April 18th. StockNews.com cut shares of Lantheus from a “buy” rating to a “hold” rating in a research note on Friday, May 3rd. JMP Securities lifted their price objective on shares of Lantheus from $100.00 to $130.00 and gave the company an “outperform” rating in a research report on Wednesday. Finally, Mizuho lifted their price objective on shares of Lantheus from $90.00 to $100.00 and gave the company a “buy” rating in a research report on Friday, May 3rd. Two equities research analysts have rated the stock with a hold rating and seven have issued a buy rating to the company’s stock. According to data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $113.86.

Get Our Latest Report on LNTH

Lantheus Price Performance

Shares of NASDAQ:LNTH opened at $106.18 on Thursday. The firm’s 50 day moving average price is $80.10 and its 200-day moving average price is $66.95. Lantheus has a twelve month low of $50.20 and a twelve month high of $106.99. The company has a quick ratio of 4.55, a current ratio of 4.84 and a debt-to-equity ratio of 0.59. The stock has a market capitalization of $7.36 billion, a PE ratio of 16.21 and a beta of 0.51.

Lantheus (NASDAQ:LNTHGet Free Report) last issued its quarterly earnings data on Thursday, May 2nd. The medical equipment provider reported $1.51 earnings per share for the quarter, topping the consensus estimate of $1.40 by $0.11. Lantheus had a net margin of 33.72% and a return on equity of 54.10%. The firm had revenue of $369.98 million for the quarter, compared to analysts’ expectations of $349.46 million. Equities research analysts expect that Lantheus will post 6.46 EPS for the current year.

Insider Activity at Lantheus

In other Lantheus news, insider Daniel Niedzwiecki sold 12,873 shares of Lantheus stock in a transaction on Thursday, May 30th. The shares were sold at an average price of $79.86, for a total transaction of $1,028,037.78. Following the completion of the transaction, the insider now directly owns 80,244 shares of the company’s stock, valued at $6,408,285.84. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. In other Lantheus news, insider Daniel Niedzwiecki sold 12,873 shares of Lantheus stock in a transaction on Thursday, May 30th. The shares were sold at an average price of $79.86, for a total transaction of $1,028,037.78. Following the completion of the transaction, the insider now directly owns 80,244 shares of the company’s stock, valued at $6,408,285.84. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. Also, Director Heinz Christoph Maeusli sold 18,373 shares of Lantheus stock in a transaction on Tuesday, May 28th. The stock was sold at an average price of $79.19, for a total transaction of $1,454,957.87. Following the transaction, the director now directly owns 23,340 shares of the company’s stock, valued at $1,848,294.60. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 32,269 shares of company stock valued at $2,557,300. 2.10% of the stock is owned by corporate insiders.

Institutional Inflows and Outflows

A number of hedge funds have recently made changes to their positions in LNTH. Farallon Capital Management LLC grew its holdings in shares of Lantheus by 595.3% in the first quarter. Farallon Capital Management LLC now owns 1,483,227 shares of the medical equipment provider’s stock worth $92,316,000 after purchasing an additional 1,269,900 shares during the last quarter. Norges Bank bought a new position in shares of Lantheus in the fourth quarter worth about $29,956,000. Reinhart Partners LLC. grew its holdings in shares of Lantheus by 50.4% in the fourth quarter. Reinhart Partners LLC. now owns 1,356,273 shares of the medical equipment provider’s stock worth $84,089,000 after purchasing an additional 454,753 shares during the last quarter. Swedbank AB bought a new position in shares of Lantheus in the first quarter worth about $26,346,000. Finally, Nomura Holdings Inc. grew its holdings in shares of Lantheus by 105.3% in the fourth quarter. Nomura Holdings Inc. now owns 20,678 shares of the medical equipment provider’s stock worth $1,282,000 after purchasing an additional 407,507 shares during the last quarter. 99.06% of the stock is currently owned by institutional investors.

Lantheus Company Profile

(Get Free Report)

Lantheus Holdings, Inc develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer.

See Also

Analyst Recommendations for Lantheus (NASDAQ:LNTH)

Receive News & Ratings for Lantheus Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Lantheus and related companies with MarketBeat.com's FREE daily email newsletter.